Skip to main content

Table 1 Comparison of the demographic and clinical characteristics between multiple sclerosis (MS) patients and non-MS controls in the merged dataset and in the validation group

From: N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis

  Datasets Validation
MS (n = 61) Non-MS (31) P MS (n = 11) Non-MS (n = 3) P
Age (years) 44.87 ± 15.66 42.71 ± 12.00 0.466 29.73 ± 10.78 42.33 ± 11.85 0.195
Sex (%)
 Female 37 (60.7%) 19 (61.3%) 0.953 8 (72.7%) 2 (66.7%) 0.837
 Male 24 (39.3%) 12 (38.7%)   3 (27.3%) 1 (33.3%)  
Subtype (%)
 RRMS 32 (52.5%) 8 (72.7%)
 PPMS 10 (16.4%)   1 (9.1%)  
 SPMS 19 (31.1%)   2 (18.2%)  
DMDs (%) 3 (27.3%)
CSF testing
 OB (%) 1 (16.7%)
 Antibody (%) (anti-AQP4, MOG, MBP)     0 (0.0%)   
  1. In the validation group, six of the 11 MS patients underwent CSF OB testing, and only one patient found positive result. Nine of them measured related antibodies while all reported negative results